Cas:1346597-47-4 Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate manufacturer & supplier

Chemical Name:Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate

CAS.NO:1346597-47-4

Synonyms:Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate

Molecular Formula:C₁₃H₁₇F₂NO₂

Molecular Weight:257.27600

HS Code:2922499990

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:29.54000

Exact Mass:257.12300

LogP:2.31680

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate Use and application,Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate technical grade,usp/ep/jp grade.

Related News: Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate manufacturer Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate supplier Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes. Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate vendor Fears over the continuing spread of coronavirus have also fueled resentment and discrimination. Some have become outcasts in their own country, shunned by hotels, neighbors and — in some areas — placed under controversial quarantine measures. Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate factory Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients.